These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31869855)

  • 1. Suppressing 'nonsense' in cystic fibrosis.
    Hinzpeter A; Sermet-Gaudelus I; Sheppard DN
    J Physiol; 2020 Feb; 598(3):429-430. PubMed ID: 31869855
    [No Abstract]   [Full Text] [Related]  

  • 2. Ataluren/ivacaftor combination therapy: Two N-of-1 trials in cystic fibrosis patients with nonsense mutations.
    Peabody Lever JE; Mutyam V; Hathorne HY; Peng N; Sharma J; Edwards LJ; Rowe SM
    Pediatr Pulmonol; 2020 Jul; 55(7):1838-1842. PubMed ID: 32281737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: The current pipeline of therapeutics.
    Goralski JL; Davis SD
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40():S66-73. PubMed ID: 26335956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrector combination therapies for F508del-CFTR.
    Hanrahan JW; Matthes E; Carlile G; Thomas DY
    Curr Opin Pharmacol; 2017 Jun; 34():105-111. PubMed ID: 29080476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of Cystic Fibrosis with CFTR Modulators].
    Tümmler B
    Pneumologie; 2016 May; 70(5):301-13. PubMed ID: 26894479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic Cochrane Review of correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Paediatr Respir Rev; 2019 Apr; 30():25-26. PubMed ID: 31128877
    [No Abstract]   [Full Text] [Related]  

  • 11. [New therapies for cystic fibrosis targeting the CFTR gene or the CFTR protein].
    Hubert D; Bui S; Marguet C; Colomb-Jung V; Murris-Espin M; Corvol H; Munck A
    Rev Mal Respir; 2016 Oct; 33(8):658-665. PubMed ID: 26806675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.
    Antoniu SA
    Expert Opin Investig Drugs; 2011 Mar; 20(3):423-5. PubMed ID: 21303308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple CFTR Modulator Therapy for Cystic Fibrosis.
    Holguin F
    N Engl J Med; 2018 Oct; 379(17):1671-1672. PubMed ID: 30334694
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: a basis for read-through therapies in cystic fibrosis.
    Clarke LA; Awatade NT; Felício VM; Silva IA; Calucho M; Pereira L; Azevedo P; Cavaco J; Barreto C; Bertuzzo C; Gartner S; Beekman J; Amaral MD
    Hum Mutat; 2019 Mar; 40(3):326-334. PubMed ID: 30488522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
    Bulloch MN; Hanna C; Giovane R
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A little CFTR can change a lot: slowing cystic fibrosis progression.
    Rowe SM
    Lancet Respir Med; 2017 Feb; 5(2):86-87. PubMed ID: 28011036
    [No Abstract]   [Full Text] [Related]  

  • 17. CFTR mutations and cystic fibrosis.
    Prescrire Int; 2013 Oct; 22(142):232. PubMed ID: 24298580
    [No Abstract]   [Full Text] [Related]  

  • 18. Nonsense-mediated RNA Decay Pathway Inhibition Restores Expression and Function of W1282X CFTR.
    Keenan MM; Huang L; Jordan NJ; Wong E; Cheng Y; Valley HC; Mahiou J; Liang F; Bihler H; Mense M; Guo S; Monia BP
    Am J Respir Cell Mol Biol; 2019 Sep; 61(3):290-300. PubMed ID: 30836009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of N-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent.
    Van der Plas SE; Kelgtermans H; De Munck T; Martina SLX; Dropsit S; Quinton E; De Blieck A; Joannesse C; Tomaskovic L; Jans M; Christophe T; van der Aar E; Borgonovi M; Nelles L; Gees M; Stouten P; Van Der Schueren J; Mammoliti O; Conrath K; Andrews M
    J Med Chem; 2018 Feb; 61(4):1425-1435. PubMed ID: 29148763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tobramycin is a suppressor of premature termination codons.
    Altamura N; Castaldo R; Finotti A; Breveglieri G; Salvatori F; Zuccato C; Gambari R; Panin GC; Borgatti M
    J Cyst Fibros; 2013 Dec; 12(6):806-11. PubMed ID: 23540394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.